Philippines suspends world-first dengue vaccine after maker warns it could make some cases even worse
It was the first country to adopt widespread use of the vaccine Dengvaxia in 2016, and has since given it to more than 700,000 children
The Philippines said on Friday it had suspended use of a landmark vaccine for the potentially deadly dengue virus after its manufacturer warned it could worsen the disease in some cases.
French pharmaceutical giant Sanofi announced on Wednesday that its world-first dengue vaccine could lead to more severe symptoms for people who had not previously been infected.
The Philippines has vaccinated more than 733,000 children with Dengvaxia since 2016 when it became the first country to start using it on a mass scale. But it said on Friday the programme had been suspended.
More cases of severe disease could occur following vaccination upon a subsequent dengue infection
“In the light of this new analysis, the DOH (Department of Health) will place the dengue vaccination programme on hold while review and consultation is ongoing with experts, key stakeholders, and the WHO (World Health Organisation),” Health Secretary Francisco Duque said.
Sanofi had initially said its Dengvaxia vaccine was “critical” in the fight against dengue, the world’s most common mosquito-borne virus.
It said on Wednesday that a new study has confirmed Dengvaxia’s benefits for “those who had prior infection”.
“For those not previously infected by dengue virus, however, the analysis found that in the longer term, more cases of severe disease could occur following vaccination upon a subsequent dengue infection,” Sanofi said.
Duque stressed that the government had not yet received reports of any problems with Dengvaxia.